NEW YORK (GenomeWeb News) — The Medcan Clinic in Toronto will offer a genetic test that predicts patient response to the anti-clotting drug warfarin in Canada, under an agreement it signed with PGXL laboratories.
Medcan, a preventive health care clinic focused on identifying health risks before symptoms occur, said on Dec. 18 that it has signed an agreement with Louisville, Ky.-based PGXL to offer the warfarin test, which detects variations in the CYP2C9 and VCORC1 genes that are linked to warfarin response.
Medcan said that the agreement with PGXL also includes tests for “many other drug therapies,” but did not elaborate.
Medcan said that it is the first clinic to offer genetic testing for warfarin response in Canada.
Financial terms of the agreement were not released.